本帖最后由 老马 于 2012-1-13 21:20 编辑 & J+ G5 V( I8 } |
+ C. \$ u& V" [2 ~5 H: W& W$ M* E2 t
爱必妥和阿瓦斯丁的比较
# c. E3 ?# Y6 }4 U6 f: `
6 c% x0 o G$ |& y9 a
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/, U+ p z# d- Y% ?3 [( o
" D: u, @# W/ m4 j. e
$ t. T9 N3 I: ghttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/8 x0 q4 ^% |8 {# z
==================================================2 `, M) e+ m" i+ u" O6 F, Z
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)) G- j$ V% v9 g7 G5 i8 t$ T
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.. }" ]) x" i) r
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.* r) j& s/ Q" [2 c9 s
|